Corey Williams
Corey Williams's Latest Posts
BST Trade Alert: March 27, 2013
March 27, 2013 Recommendation: Buy AcelRx Pharmaceuticals (NASDAQ: ACRX) up to $5.65 per share. About the Company: ACRX has the all the characteristics of a biotech stock poised to skyrocket. A late-stage product candidate with blockbuster sales potential. A solid financial position. And a significant, fast-approaching catalyst. To say we’re excited about ACRX would be a huge […]
BST Position Update: March 22, 2013
March 22, 2013 . . . . Anacor Pharmaceuticals (NASDAQ: ANAC) – Hold It’s a good thing we decided to hang on to ANAC. The stock surged 26% yesterdayon heavy volume. And we now have a 3% gain on the position. ANAC soared on positive data from a phase 2 trial of AN2728, the company’s novel treatment for […]
SET Monthly Issue March 2013
March 2013 WHEN WILL THE S&P 500 SET A NEW RECORD HIGH? Since the start of the year, the S&P 500 has been on a fast escalator toward a new record high. Week after week, the large cap index has climbed higher. Last week the S&P reached a high of 1,563. It was just a […]
BST Position Update: March 11, 2013
March 11, 2013 . . . . Halozyme Therapeutics (NASDAQ: HALO) – Buy up to $6.00 HALO is our most recent addition to the portfolio. And to say we’re excited about another opportunity to trade this biotech, would be an understatement. The last time we traded it, our position more than doubled in value. And […]
BST Trade Alert: March 7, 2013
March 7, 2013 Recommendation: Buy Halozyme Therapeutics (NASDAQ: HALO) up to $6.00 per share. About the Company: Many of you will probably have fond memories of Halozyme Therapeutics. After all, we more than doubled our money the last time we traded this exciting biotech. It was certainly one of the biggest winners we’ve had in the portfolio. […]
SET Portfolio Update March 2013
March 5, 2013 Dear Sector ETF Trader Reader, As I write this morning, the Dow is hitting new all-time highs. It’s really amazing how far the market has come over the last four years. And now the large cap index has erased all of the losses it sustained in the financial crisis. This is obviously […]
SET Monthly Issue February 2013
February 2013 CAN THE S&P MAKE IT 8? As we kick off this President’s Day shortened week, the S&P is riding a seven-week winning streak. An impressive run to be sure… Investors everywhere are wondering if this will be the eighth week of the rally or the start of a correction. Over the last few […]
BST Position Update: February 15, 2013
February 15, 2013 . . . . MannKind (NASDAQ: MNKD) – Buy up to $2.85 MNKD is our latest addition to the portfolio. And we’re very excited about it to say the least. They’re developing a potential blockbuster drug called Afrezza for type 1 and type 2 diabetes. Why are we so high on Afrezza? […]
BST Sell Alert: February 8, 2013
February 8, 2013 Sell OPKO Health (NYSE: OPK) OPK has been red hot since early December. But now it appears the rally has ended. With the shares dropping substantially today on no news, let’s go ahead and capture our profits of 44%! Go ahead and sell OPKO Health (NYSE: OPK) as soon as possible. Congratulations on a very […]
SET Portfolio Update February 2013
February 5, 2013 Dear Sector ETF Trader Reader, Stocks have shot out of the gate to start the year. The S&P 500 is up more than 3% to around 1,500 and Dow has gained more than 4% to around 14,000 in about a month. There’s no doubt about it, those are impressive gains for the […]
